SecBot SecBot
SECBOTREPLAY Home › Report › MRK

MRK · Merck lost its constitutional challenge to the IRA's Medicare Drug…

Merck & Co., Inc. · COURT-RULING filed Aug 23, 2026 at 20:00 ET

At the news

BEARISHIMPACT 5/10

COURT-RULING filed Aug 23, 2026 at 20:00 ET

Merck lost its constitutional challenge to the IRA's Medicare Drug Price Negotiation Program in D.C. District Court. The court granted summary judgment to the government on all claims, rejecting Merck's arguments that the program constitutes an uncompensated taking, compels speech, or imposes unconstitutional conditions. This ruling, consistent with multiple circuit court decisions, removes a key legal obstacle to price negotiation on Merck's drug Januvia and other selected drugs, though the practical revenue impact depends on the negotiated price and Merck's participation decision. The stock has already rallied significantly in recent weeks, suggesting the market had largely discounted this outcome, and the ruling is subject to appeal to the D.C. Circuit, where Merck may seek a stay pending appeal.

  • Merck's motion for summary judgment was DENIED in full; the government's cross-motion was GRANTED in full.
  • The court ruled that Merck's participation in the Drug Price Negotiation Program is voluntary because it can withdraw from Medicare and Medicaid programs, precluding a takings claim.
  • The court rejected Merck's First Amendment challenge, finding that any compelled speech in the program agreements is incidental to the regulation of conduct.
  • Merck's diabetes drug Januvia was selected for price negotiation under the IRA program.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access